MorphoSys, Incyte gets an early FDA nod for Monjuvi, an alternative to CAR-T for B-cell malignancies
MorphoSys and Incyte announced the US FDA approval under accelerated approval for their treatment Monjuvi in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) – the most common form of non-Hodgkin lymphoma.
Not long ago, the companies inked an oncology pact to develop and commercialize MorphoSys' anti-CD19 antibody Monjuvi jointly. MorphoSys in-licensed Monjuvi, which is a humanized Fc-engineered monoclonal antibody against CD19 – the same protein which CAR-T cell therapies target and is in abund...
